Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent versus continuous androgen blockade for biochemical recurrence after radiotherapy in prostate cancer
2006-001909-28Phase 4Active
- Sponsor
- GICOR
- Start
- Mar 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buserelin, goserelin, leuprolide and triptorelin in prostate cancer (PCa) (2 arms), sponsored by GICOR. Started Mar 2010; status: active.
02
Drugs
buserelingoserelinleuprolidetriptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2006-001909-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001909-28.